Heart Attack Diagnostics Market By Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, Others), By End User (Hospitals, Diagnostics Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Heart Attack Diagnostics Market

The heart attack diagnostics market was valued at $9.2 billion in 2023 and is projected to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.

Heart attack diagnostic comprises of diagnosing the blood pressure, temperature, and pulse rate of a patient. A series of evaluations are conducted to determine if an individual has experienced a heart attack, also known as myocardial infarction. The series of diagnostic tests includes an electrocardiogram (EKG) which measures the electrical activity of heart, blood tests to detect cardiac enzymes such as troponin which are released into the bloodstream in case of heart muscle damage, and imaging tests such as coronary angiography or echocardiography for the visualization of heart & its blood vessels.

Increase in sedentary lifestyles has led to surge in occurrence of lifestyle diseases, including heart attack. This has led to surge in demand for heart attack diagnostics, hence augmenting the growth of the market. Furthermore, exponential growth in the geriatric population globally is opening avenues for the expansion of the market. The assimilation of AI in the EKG testing is poised to become mainstream in the future as it reduces the diagnosis time. A hospital in Taiwan conducted research regarding the assimilation of AI and EKG, which reduced the diagnosis period by 10 minutes. Constant improvements in AI are enhancing the efficacy of clinical decision support system, encouraging medical practitioners to adopt the technology.

However, these diagnostics tests are extremely expensive and prevent several end users from leveraging their benefits, hence restraining the market development. In addition, the introduction of new diagnostic technologies is subject to various regulatory hurdles, hence presenting challenges for the expansion of the market. Different regulatory bodies such as the U.S. Food and Drug Administration, European Medicines Agency, the Pharmaceuticals and Medical Devices Agency in Japan, and Central Drugs Standard Control Organization in India have mandated the adherence to their respective regulatory guidelines for the entry of new diagnostic technologies into the market. Contrarily, innovative techniques being introduced into the market are an indicator of its promising future. For instance, Siemens Healthineers, a German healthcare company, has introduced a handheld device which claims to detect heart attack in less than 30 minutes. The launch of such devices is expected to quicken treatment delivery and increase the chances of recovery for patients in the future.

Segment Review

The heart attack diagnostics market is segmented into type, end user, and region. On the basis of type, the market is divided into electrocardiogram, blood tests, angiogram, computerized cardiac tomography, and others. By end user, it is classified into hospitals, diagnostics centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Competition Analysis

The major players operating in the global heart attack diagnostics market include Bionet Co., Ltd, TOSHIBA CORPORATION, Bio-Rad Laboratories Inc, Life Sign LLC, Schiller AG, Beckman Coulter,Inc., GE Healthcare, Hitachi Medical Systems, F. Hoffmann-La Roche Ltd., and Abbott Laboratories. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Type

Electrocardiogram
Blood Tests
Angiogram
Computerized Cardiac Tomography
Others

By End User

Hospitals
Diagnostics Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Bionet Co., Ltd
TOSHIBA CORPORATION
Bio-Rad Laboratories Inc
Life Sign LLC
Schiller AG
Beckman Coulter,Inc.
GE Healthcare
Hitachi Medical Systems
F. Hoffmann-La Roche Ltd.
Abbott Laboratories

Product Code: A12689

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities

CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Electrocardiogram
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Blood Tests
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Angiogram
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Computerized Cardiac Tomography
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country

CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Diagnostics Centers
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Others
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Type
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Heart Attack Diagnostics Market
  - 6.2.5.1. Market Size and Forecast, By Type
  - 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Heart Attack Diagnostics Market
  - 6.2.6.1. Market Size and Forecast, By Type
  - 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Heart Attack Diagnostics Market
  - 6.2.7.1. Market Size and Forecast, By Type
  - 6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Type
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. France Heart Attack Diagnostics Market
  - 6.3.5.1. Market Size and Forecast, By Type
  - 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. Germany Heart Attack Diagnostics Market
  - 6.3.6.1. Market Size and Forecast, By Type
  - 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. Italy Heart Attack Diagnostics Market
  - 6.3.7.1. Market Size and Forecast, By Type
  - 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Spain Heart Attack Diagnostics Market
  - 6.3.8.1. Market Size and Forecast, By Type
  - 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. UK Heart Attack Diagnostics Market
  - 6.3.9.1. Market Size and Forecast, By Type
  - 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Heart Attack Diagnostics Market
  - 6.3.10.1. Market Size and Forecast, By Type
  - 6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Type
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. China Heart Attack Diagnostics Market
  - 6.4.5.1. Market Size and Forecast, By Type
  - 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. Japan Heart Attack Diagnostics Market
  - 6.4.6.1. Market Size and Forecast, By Type
  - 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. India Heart Attack Diagnostics Market
  - 6.4.7.1. Market Size and Forecast, By Type
  - 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. South Korea Heart Attack Diagnostics Market
  - 6.4.8.1. Market Size and Forecast, By Type
  - 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. Australia Heart Attack Diagnostics Market
  - 6.4.9.1. Market Size and Forecast, By Type
  - 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
  - 6.4.10.1. Market Size and Forecast, By Type
  - 6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Type
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Heart Attack Diagnostics Market
  - 6.5.5.1. Market Size and Forecast, By Type
  - 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. South Africa Heart Attack Diagnostics Market
  - 6.5.6.1. Market Size and Forecast, By Type
  - 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. Saudi Arabia Heart Attack Diagnostics Market
  - 6.5.7.1. Market Size and Forecast, By Type
  - 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
  - 6.5.8.1. Market Size and Forecast, By Type
  - 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

8.1. Bionet Co., Ltd
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
8.2. TOSHIBA CORPORATION
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
8.3. Bio-Rad Laboratories Inc
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
8.4. Life Sign LLC
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
8.5. Schiller AG
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
8.6. Beckman Coulter, Inc.
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
8.7. GE Healthcare
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
8.8. Hitachi Medical Systems
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
8.9. F. Hoffmann-La Roche Ltd.
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
8.10. Abbott Laboratories
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments